glp-1 with medicaid US states drop coverage of weight-loss drugs as demand rises | US healthcare Pennsylvania Medicaid stopped covering GLP-1s

GIP receptors exist in fat tissue, bone, and the brain

Most people do best when the medication supports a plan instead of standing in for one: steady protein, regular movement, and enough sleep

Their stability, solubility, and ultimately, their biological activity, are highly sensitive to their environment

Physical activity brings oxygen to the brain, resulting in a revitalized feeling

Source: Evaluate Pharma, World Obesity Federation, Putnam Analysis Q2, 2025 Unmet Needs and Potential Differentiation Levers Despite extraordinary promise, there are still unmet needs that biopharma companies can target to address: GI Tolerability The most common GI adverse events (nausea, vomiting, and diarrhea) often lead to therapy discontinuation